Showing 501 - 520 results of 6,075 for search '"Canada"', query time: 0.05s Refine Results
  1. 501

    Canadian Cardiovascular Society and Canadian Thoracic Society Position Statement on Pulmonary Arterial Hypertension by David Langleben, Stephen Archer, John Granton, Andrew M Hirsch, Robert D Levy, Sanjay Mehta, Evangelos Michelakis, Duncan J Stewart

    Published 2005-01-01
    “…The present document is intended to act as an update for the clinician, to provide a template for the initial evaluation of patients, to enable the understanding of current therapeutic paradigms based on approved indications for Canada, to highlight new therapies on the horizon, and to state the positions of the Canadian Cardiovascular Society and the Canadian Thoracic Society on resource management for pulmonary arterial hypertension in Canada.…”
    Get full text
    Article
  2. 502

    Safety and Efficacy of Hemospray® in Upper Gastrointestinal Bleeding by Alan Hoi Lun Yau, George Ou, Cherry Galorport, Jack Amar, Brian Bressler, Fergal Donnellan, Hin Hin Ko, Eric Lam, Robert Allan Enns

    Published 2014-01-01
    “…BACKGROUND: Hemospray (Cook Medical, USA) has recently been approved in Canada for the management of nonvariceal upper gastrointestional bleeding (UGIB).…”
    Get full text
    Article
  3. 503
  4. 504

    Humoral and cell-mediated immune responses to COVID-19 vaccines up to 6 months post three-dose primary series in adults with inborn errors of immunity and their breakthrough infect... by Dana Unninayar, Emilia L. Falcone, Hugo Chapdelaine, Donald C. Vinh, Karina A. Top, Beata Derfalvi, Thomas B. Issekutz, Hélène Decaluwe, Anne Pham-Huy, Julia Upton, Stephen D. Betschel, Tamar Rubin, Sneha Suresh, Nicola A. M. Wright, Luis Murguía-Favela, Tatiana Kalashnikova, Lisa Barrett, Sharon Oldford, Marc-Andre Langlois, Corey Arnold, Manish Sadarangani, Tinghua Zhang, Tim Ramsay, Dina Yazji, Juthaporn Cowan, Juthaporn Cowan

    Published 2025-01-01
    “…Therefore, the purpose of this study was to examine HI and CMI responses up to 6 months post-COVID-19 vaccine dose 3 in adults with IEIs.MethodsA multi-center prospective observational study was conducted across Canada to collect severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)-specific HI and CMI data at 4- and 24-week intervals after vaccine doses 2 and 3 (D2 + 4wk/D2 + 24wk/D3 + 4wk/D3 + 24wk).ResultsA total of 149 adults with IEIs and 423 healthy controls were recruited from July 2021 to October 2023. …”
    Get full text
    Article
  5. 505
  6. 506
  7. 507
  8. 508
  9. 509
  10. 510

    Seroprevalences of Hepatitis B Virus and Hepatitis C Virus among Participants of an Asian Health Fair in the Lower Mainland, British Columbia by Stephen Ip, Jo-Ann Ford, Kirby Lau, Vladimir Marquez, Marisa Guan, Carolyn Klassen, Jessica Chan, WC Peter Kwan, Mel Krajden, Eric M Yoshida

    Published 2015-01-01
    “…BACKGROUND: The seroprevalences of hepatitis B virus (HBV) and hepatitis C virus (HCV) are 0.4% and 0.8%, respectively, in Canada, but varying rates have been reported in different populations.…”
    Get full text
    Article
  11. 511
  12. 512
  13. 513
  14. 514
  15. 515
  16. 516
  17. 517
  18. 518
  19. 519
  20. 520